Porphyrin-Based Tumor-Targeting Theranostic Agent: Gd-TDAP.
Soyeon KimJi-Ung YangJae Hun AhnIn Ok KoJung Young KimYong Jin LeeJi Ae ParkPublished in: ACS medicinal chemistry letters (2021)
The aim of this work was to evaluate a tumor-targeting porphyrin-based gadolinium complex (Gd-TDAP) for use as an MR/optical imaging agent and potential therapeutic agent. Gd-TDAP had higher longitudinal relaxivity (11.8 mM-1 s-1) than a commercial MRI contrast agent (Omniscan; 3.7 mM-1 s-1) in HSA solution (0.67 mM) at 3 T. The tumor-targeting characteristics were confirmed by T1-weighted MR imaging and optical imaging using an orthotopic brain tumor mouse model, which showed 1.3-fold higher uptake in tumor compared to normal brain tissues. The cell fraction data using U87MG glioblastoma cells indicated the potential for gadolinium neutron capture therapy (Gd-NCT), which requires gadolinium to be inside the cell nucleus. In addition, porphyrin derivatives can be used for photodynamic therapy (PDT), and the results demonstrated that Gd-TDAP has great potential not only as a bimodal imaging agent but also for treatment.
Keyphrases
- photodynamic therapy
- contrast enhanced
- high resolution
- fluorescence imaging
- magnetic resonance imaging
- magnetic resonance
- mouse model
- single cell
- cancer therapy
- cell therapy
- stem cells
- machine learning
- diffusion weighted imaging
- big data
- oxidative stress
- cross sectional
- risk assessment
- electronic health record
- human health
- cell death
- subarachnoid hemorrhage
- deep learning